1. Home
  2. CHGG vs BMEA Comparison

CHGG vs BMEA Comparison

Compare CHGG & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chegg Inc.

CHGG

Chegg Inc.

HOLD

Current Price

$0.89

Market Cap

103.4M

Sector

Real Estate

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.03

Market Cap

96.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHGG
BMEA
Founded
2005
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.4M
96.9M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
CHGG
BMEA
Price
$0.89
$1.03
Analyst Decision
Sell
Strong Buy
Analyst Count
5
7
Target Price
$1.42
$8.71
AVG Volume (30 Days)
3.0M
1.2M
Earning Date
11-10-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$447,733,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.87
52 Week High
$2.73
$7.46

Technical Indicators

Market Signals
Indicator
CHGG
BMEA
Relative Strength Index (RSI) 39.00 34.94
Support Level $0.87 $0.87
Resistance Level $1.01 $1.12
Average True Range (ATR) 0.11 0.09
MACD 0.00 0.00
Stochastic Oscillator 4.93 27.93

Price Performance

Historical Comparison
CHGG
BMEA

About CHGG Chegg Inc.

Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Subscription Services, which encompasses Chegg Study Pack, Chegg Study, Chegg Writing, Chegg Math, and Busuu offerings that can be accessed internationally through the company's websites and on mobile devices, and Skills and Other, which encompasses skills, advertising services, print textbooks, and eTextbooks offerings.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: